A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer

P Iversen, TLJ Tammela, S Vaage, O Lukkarinen, P Lodding, T Bull-Njaa, J Viitanen, P Hoisaeter, P Lundmo, F Rasmussen, J-E Johansson, B-E Persson, K Caroll

    Research output: Contribution to journalArticleScientificpeer-review

    51 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)204-211
    JournalEuropean Urology
    Volume42
    Publication statusPublished - 2002
    Publication typeA1 Journal article-refereed

    Keywords

    • bicalutamide
    • disease progression
    • early prostate cancer
    • standard care

    Cite this